Publication at First Faculty of Medicine |
2018
Abstract
Tocilizumab is a monoclonal antibody to the interleukin 6 receptor (IL-6), used in the treatment of rheumatoid arthritis. IL-6 is involved in a series of pro-inflammatory cascades in rheumatoid arthritis leading to chronic autoimmune inflammatory response and, finally, to structural joint damage.
Blocking IL-6 has become an alternative in the treatment of patients with rheumatoid arthritis who have failed not only prior drug-modifying therapy but also biological therapies. Tocilizumab can be administered in two ways in the efficacy and safety of comparable forms: intravenous and subcutaneous.
This work focuses on the effect and safety of the subcutaneous form of tocilizumab